复宏汉霖(02696)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02696 复宏汉霖

未开盘 01-13 16:08:13

68.750

+4.150

+6.42%

最高71.450	最低64.100	成交量102.82万
今开64.100	昨收64.600	日振幅11.38%
总市值373.65亿	流通市值112.36亿	总股本5.43亿
成交额7,134万	换手率0.63%	流通股本1.63亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02696","market":"HK","secType":"STK","nameCN":"复宏汉霖","latestPrice":68.75,"timestamp":1768291693005,"preClose":64.6,"halted":0,"volume":1028246,"delay":0,"floatShares":163428541,"shares":543494853,"eps":1.6883160336068899,"marketStatus":"未开盘","change":4.15,"latestTime":"01-13 16:08:13","open":64.1,"high":71.45,"low":64.1,"amount":71343074,"amplitude":0.113777,"askPrice":68.75,"askSize":400,"bidPrice":68.65,"bidSize":500,"shortable":3,"etf":0,"ttmEps":1.6961893796299188,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1768354200000},"marketStatusCode":0,"adr":0,"listingDate":1569340800000,"exchange":"SEHK","adjPreClose":64.6,"openAndCloseTimeList":[[1768267800000,1768276800000],[1768280400000,1768291200000]],"volumeRatio":1.400041,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02696","defaultTab":"news","newsList":[{"id":"1133202853","title":"复宏汉霖贝伐珠单抗注射液汉贝泰®获FDA受理生物制品许可申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1133202853","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1133202853?lang=zh_cn&edition=full","pubTime":"2026-01-13 16:53","pubTimestamp":1768294393,"startTime":"0","endTime":"0","summary":"上海复宏汉霖生物技术股份有限公司宣布，其自主研发的贝伐珠单抗注射液（商品名：汉贝泰®）的生物制品许可申请（BLA）已正式获得美国食品药品监督管理局（FDA）受理。此次受理标志着该产品向进入美国市场迈出关键一步，也彰显了公司创新研发实力与国际注册能力的提升。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000306685.HKD","HK0000306701.USD","02696","HK0000320264.USD","HK0000165453.HKD","BK1161","HK0000320223.HKD"],"gpt_icon":0},{"id":"2603501958","title":"复宏汉霖(02696)：汉贝泰® (贝伐珠单抗注射液)的生物制品许可申请(BLA) 获美国食品药品管理局(FDA)受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2603501958","media":"智通财经","labels":["productRelease"],"top":1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603501958?lang=zh_cn&edition=full","pubTime":"2026-01-13 16:53","pubTimestamp":1768294388,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复宏汉霖(02696)发布公告，近日，公司自主研发的汉贝泰® (贝伐珠单抗注射液)(“汉贝泰®”)的生物制品许可申请(“BLA”)获美国食品药品管理局(“FDA”)受理，本次申请涉及的适应症包括：(1)转移性结直肠癌; (2)联合卡铂和紫杉醇一线治疗不可切除的局部晚期、复发性或转移性非鳞状非小细胞肺癌;(3)复发性成人胶质母细胞瘤;(4)联合干扰素α治疗转移性肾细胞癌;(5)上皮性卵巢癌、输卵管癌或原发性腹膜癌;及(6)联合紫杉醇和顺铂，或紫杉醇和拓扑替康治疗持续性、复发性或转移性宫颈癌。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1392204.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"复宏汉霖(02696)：汉贝泰® (贝伐珠单抗注射液)的生物制品许可申请(BLA) 获美国食品药品管理局(FDA)受理","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000306701.USD","HK0000306685.HKD","HK0000320223.HKD","BK1161","02696","HK0000165453.HKD","HK0000320264.USD"],"gpt_icon":0},{"id":"2603636735","title":"每日卖空追踪 | 复宏汉霖 01月13日卖空量成交3.15万股，卖空比例为3.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603636735","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603636735?lang=zh_cn&edition=full","pubTime":"2026-01-13 16:30","pubTimestamp":1768293032,"startTime":"0","endTime":"0","summary":"复宏汉霖北京时间01月13日，涨6.42%，卖空量成交3.15万股，较上一交易日增加104.55%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260113164507a714fe11&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260113164507a714fe11&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02696","HK0000320264.USD","HK0000320223.HKD","HK0000165453.HKD","HK0000306701.USD","HK0000306685.HKD"],"gpt_icon":0},{"id":"2603539575","title":"港股异动 | 复宏汉霖(02696)再涨超8% 广谱抗肿瘤PD-L1 ADC HLX43末线食管鳞癌II期数据首次发布","url":"https://stock-news.laohu8.com/highlight/detail?id=2603539575","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603539575?lang=zh_cn&edition=full","pubTime":"2026-01-13 10:12","pubTimestamp":1768270333,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，复宏汉霖再涨超8%，截至发稿，涨8.05%，报69.8港元，成交额1864.08万港元。消息面上，1月9日，复宏汉霖在2026年美国临床肿瘤学会胃肠道肿瘤研讨会上，首度公布了其PD-L1 ADC HLX43治疗复发/转移性食管鳞癌的II期概念验证数据，本次发布的数据初步验证了HLX43在经治的晚期ESCC患者中的治疗潜力，展现出令人鼓舞的疗效及良好的安全性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1392033.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1169590202.USD","HK0000165453.HKD","BK4231","LU1169589451.USD","HK0000320223.HKD","BK4023","BK1161","02696","HK0000320264.USD","ADC","HK0000306701.USD","BK4080","PD","HK0000306685.HKD"],"gpt_icon":0},{"id":"2603636788","title":"复宏汉霖盘中异动 早盘快速上涨5.03%报67.850港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2603636788","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603636788?lang=zh_cn&edition=full","pubTime":"2026-01-13 09:44","pubTimestamp":1768268665,"startTime":"0","endTime":"0","summary":"2026年01月13日早盘09时44分，复宏汉霖股票出现异动，股价快速拉升5.03%。截至发稿，该股报67.850港元/股，成交量7.54万股，换手率0.05%，振幅6.42%。资金方面，该股资金流入414.538万港元，流出85.6295万港元。复宏汉霖股票所在的生物技术行业中，整体涨幅为1.08%。复宏汉霖公司简介：上海复宏汉霖生物技术股份有限公司是一家主要从事单克隆抗体产品的研发、生产及销售业务的中国公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026011309442697a1861a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026011309442697a1861a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HK0000320223.HKD","HK0000306685.HKD","02696","HK0000320264.USD","HK0000306701.USD","BK1161","HK0000165453.HKD"],"gpt_icon":0},{"id":"2602739341","title":"每日卖空追踪 | 复宏汉霖 01月08日卖空量成交1.09万股，卖空比例为1.51%","url":"https://stock-news.laohu8.com/highlight/detail?id=2602739341","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602739341?lang=zh_cn&edition=full","pubTime":"2026-01-08 16:30","pubTimestamp":1767861034,"startTime":"0","endTime":"0","summary":"复宏汉霖北京时间01月08日，涨3.6%，卖空量成交1.09万股，较上一交易日减少70.78%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260108164905a7023ec0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260108164905a7023ec0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HK0000306701.USD","HK0000306685.HKD","02696","HK0000320264.USD","HK0000165453.HKD","BK1161","HK0000320223.HKD"],"gpt_icon":0},{"id":"2601562331","title":"港股异动 | 复宏汉霖(02696)盘中涨超5% 公司首次公布PD-L1 ADC食管鳞状细胞癌Ⅱ期临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2601562331","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601562331?lang=zh_cn&edition=full","pubTime":"2026-01-08 11:18","pubTimestamp":1767842338,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，复宏汉霖盘中涨超5%，截至发稿，涨4.39%，报66.65港元，成交额2390.53万港元。其中，复宏汉霖首次公布其PD-L1 ADC药物HLX43治疗复发/转移性食管鳞状细胞癌中的临床数据。HLX43是靶向PD-L1的新型ADC药物，兼具免疫检查点抑制与细胞毒性双重作用，其I期临床已证实对免疫治疗无效患者具有前景疗效和良好耐受性。本项Ⅱ期研究旨在评估HLX43用于经治复发 / 转移性食管鳞状细胞癌患者的疗效与安全性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1390237.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02696","BK4023","BK4080","BK4231","LU1169590202.USD","ADC","BK1161","HK0000165453.HKD","PD","LU1169589451.USD"],"gpt_icon":0},{"id":"2601333305","title":"26ASCO GI丨复宏汉霖首次公布PD-L1 ADC食管鳞癌Ⅱ期数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2601333305","media":"药研网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601333305?lang=zh_cn&edition=full","pubTime":"2026-01-08 08:00","pubTimestamp":1767830431,"startTime":"0","endTime":"0","summary":"2026年ASCO GI会议即将在召开，官方公布了本次胃肠道肿瘤研讨会摘要内容。其中，复宏汉霖首次公布其PD-L1 ADC药物HLX43治疗复发/转移性食管鳞状细胞癌中的临床数据。HLX43 是靶向 PD-L1 的新型 ADC 药物，兼具免疫检查点抑制与细胞毒性双重作用，其 I 期临床已证实对免疫治疗无效患者具有前景疗效和良好耐受性。本项 Ⅱ 期研究旨在评估 HLX43 用于经治复发 / 转移性食管鳞状细胞癌患者的疗效与安全性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260108082422a4a988c9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260108082422a4a988c9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HK0000165453.HKD","BK1161","02696"],"gpt_icon":0},{"id":"2601876772","title":"每日卖空追踪 | 复宏汉霖 01月07日卖空量成交2.03万股，卖空比例为2.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601876772","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601876772?lang=zh_cn&edition=full","pubTime":"2026-01-07 16:30","pubTimestamp":1767774633,"startTime":"0","endTime":"0","summary":"复宏汉霖北京时间01月07日，涨2%，卖空量成交2.03万股，较上一交易日减少36.76%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260107163511a4a6e777&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260107163511a4a6e777&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HK0000165453.HKD","02696","BK1161"],"gpt_icon":0},{"id":"1113453434","title":"上海复宏汉霖（02696）12月无新增发行，股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1113453434","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1113453434?lang=zh_cn&edition=full","pubTime":"2026-01-06 17:20","pubTimestamp":1767691245,"startTime":"0","endTime":"0","summary":"上海复宏汉霖生物技术股份有限公司于2026年1月6日公布截至2025年12月31日的股份变动月报表。报告显示，公司本月未有新增发行、购回或注销股份，各类股本维持不变。公司注册股本仍为人民币543,494,853元，包括163,428,541股于香港联交所上市的H股及380,066,312股非上市股份；两类股份数量与上月持平，均无增减。期权与激励方面，2025年采纳的H股购股权计划当月无新行使或转让，仅有20,000份已失效。公司表示，将继续严格遵守香港联交所上市规则及相关法律法规。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02696"],"gpt_icon":0},{"id":"2601189294","title":"科伦博泰ITGB6靶向ADC癌症新药获批临床|复宏汉霖三款创新药IND同期获受理|和黄医药赛沃替尼申报上市并获纳入优先审评","url":"https://stock-news.laohu8.com/highlight/detail?id=2601189294","media":"中国医药创新促...","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601189294?lang=zh_cn&edition=full","pubTime":"2026-01-06 11:24","pubTimestamp":1767669859,"startTime":"0","endTime":"0","summary":"12月30日，和黄医药宣布，赛沃替尼用于经过至少2种治疗后失败的MET基因扩增的局部晚期或转移性胃癌或胃食道连接部腺癌成人患者的新药上市申请已获中国国家药品监督管理局受理，并获纳入优先审评。以上三款产品皆拟用于实体肿瘤的治疗。科伦博泰 注射用SKB1051月4日，中国国家药监局药品审评中心官网最新公示，科伦博泰申报的1类新药注射用SKB105获批临床，拟开发治疗晚期实体瘤。公开资料显示，这是一款靶向整合素β6的抗体偶联药物。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260106121530a4a199b4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260106121530a4a199b4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","BK1574","BK1587","HK0000165453.HKD","02696","00013","BK1588","BK1161","06978"],"gpt_icon":0},{"id":"2601858545","title":"每日卖空追踪 | 复宏汉霖 01月05日卖空量成交2.04万股，卖空比例为1.87%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601858545","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601858545?lang=zh_cn&edition=full","pubTime":"2026-01-05 16:30","pubTimestamp":1767601832,"startTime":"0","endTime":"0","summary":"复宏汉霖北京时间01月05日，涨6.66%，卖空量成交2.04万股，较上一交易日增加38.78%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260105163614a49e2a3e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260105163614a49e2a3e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02696","HK0000165453.HKD"],"gpt_icon":0},{"id":"2601585178","title":"3款实体瘤创新药临床申请获受理！这家生物类似药企业盘中涨近9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601585178","media":"制药网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601585178?lang=zh_cn&edition=full","pubTime":"2026-01-05 14:21","pubTimestamp":1767594097,"startTime":"0","endTime":"0","summary":"2025年12月30日，复宏汉霖宣布，三款针对实体肿瘤的潜力创新分子新药临床试验申请获国家药品监督管理局受理。HLX3901的获批受理，彰显了复宏汉霖在TCE技术领域的差异化创新实力。据悉，复宏汉霖创立于2010年，聚焦血液瘤、实体瘤、自身免疫疾病等领域，是国内较早布局生物类似药的企业。受三个创新药IND的获受理影响，2026年1月5日，复宏汉霖盘中涨近9%，截至1月5日14:14，其股价上涨6.57%，报62.45港元，成交额4692万港元，总市值339.41亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260105142352a6f4a0fa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260105142352a6f4a0fa&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","HK0000165453.HKD","BK1161","02696","06978"],"gpt_icon":0},{"id":"2601607128","title":"复宏汉霖(02696.HK)现涨近9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601607128","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601607128?lang=zh_cn&edition=full","pubTime":"2026-01-05 11:09","pubTimestamp":1767582540,"startTime":"0","endTime":"0","summary":"每经AI快讯，复宏汉霖(02696.HK)现涨近9%，截至发稿涨8.62%，报63.65港元，成交额2904.28万港元。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2026-01-05/doc-inhffmxt2198697.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-01-05/doc-inhffmxt2198697.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","02696","HK0000165453.HKD"],"gpt_icon":0},{"id":"2601071879","title":"港股异动 | 复宏汉霖(02696)现涨近9% 公司旗下三款实体瘤创新药IND同期获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2601071879","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601071879?lang=zh_cn&edition=full","pubTime":"2026-01-05 11:02","pubTimestamp":1767582152,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，复宏汉霖(02696)现涨近9%，截至发稿，涨8.62%，报63.65港元，成交额2904.28万港元。消息面上，12月30日，复宏汉霖宣布，公司三款潜力创新分子——基于自研T细胞衔接器（TCE）平台开发的DLL3xDLL3xCD3xCD28四特异性TCE HLX3901、潜在同类最优（BIC）的新型KAT6A/B口服小分子抑制剂HLX97、以及潜在同类首创（FIC）的B7H3-唾液酸酶融合蛋白HLX316的新药临床试验申请均已获得国家药品监督管理局受理。以上三款产品皆拟用于实体肿瘤的治疗。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1388498.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1574","02696","IND","HK0000165453.HKD","159992","06978"],"gpt_icon":0},{"id":"2601585438","title":"复宏汉霖盘中异动 急速拉升5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601585438","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601585438?lang=zh_cn&edition=full","pubTime":"2026-01-05 10:07","pubTimestamp":1767578836,"startTime":"0","endTime":"0","summary":"2026年01月05日早盘10时07分，复宏汉霖股票出现波动，股价快速拉升5.03%。截至发稿，该股报61.550港元/股，成交量16.27万股，换手率0.10%，振幅6.91%。机构评级方面，在所有5家参与评级的机构中，100%的券商给予买入建议，无券商给予持有、卖出建议。复宏汉霖股票所在的生物技术行业中，整体涨幅为1.30%。复宏汉霖公司简介：上海复宏汉霖生物技术股份有限公司是一家主要从事单克隆抗体产品的研发、生产及销售业务的中国公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260105100716a49ccdb9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260105100716a49ccdb9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HK0000165453.HKD","02696","BK1161"],"gpt_icon":0},{"id":"2600040688","title":"复宏汉霖注射用HLX43启动Ib/II期临床 适应症为晚期或转移性结直肠癌","url":"https://stock-news.laohu8.com/highlight/detail?id=2600040688","media":"新浪财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600040688?lang=zh_cn&edition=full","pubTime":"2026-01-04 18:03","pubTimestamp":1767520980,"startTime":"0","endTime":"0","summary":"药物临床试验登记与信息公示平台数据显示，上海复宏汉霖生物技术股份有限公司/上海复宏汉霖生物医药有限公司的一项评估HLX43联合HLX07或斯鲁利单抗在晚期或转移性结直肠癌患者中的安全性、耐受性和有效性的Ib/II期临床研究已启动。本次试验目的为评估不同剂量水平HLX43联合HLX07或斯鲁利单抗在晚期或转移性结直肠癌患者中的安全性、耐受性和有效性。注射用HLX43为生物制品，适应症为晚期或转移性结直肠癌。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260104190435a49ab0c1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260104190435a49ab0c1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02696","HK0000165453.HKD"],"gpt_icon":0},{"id":"2600040683","title":"新药周观点：2025年约101款创新药国内获批上市 行业蓬勃发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2600040683","media":"国投证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600040683?lang=zh_cn&edition=full","pubTime":"2026-01-04 00:00","pubTimestamp":1767456000,"startTime":"0","endTime":"0","summary":"本周新药行业重点分析：2025 年我国创新药行业蓬勃发展，根据NMPA 与药渡数据，2025 年NMPA 共批准了约101 款创新药，这一数量再创近年来获批新药数量的新高；其中2025 年共批准上市国产创新药（含引进）63 款， 进口创新药38 款，国内创新药行业蓬勃发展。本周新药临床申请获批准&受理情况：本周国内有18 个新药的临床申请获批准，有52 个新药的临床申请获受理。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260104174118a6f16fa6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260104174118a6f16fa6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09969","BK1161","HK0000165453.HKD","BK1574","02696","06978"],"gpt_icon":0},{"id":"2600057093","title":"新加坡政府投资公司增持复宏汉霖(02696)17.7万股 每股作价约56.76港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2600057093","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600057093?lang=zh_cn&edition=full","pubTime":"2026-01-02 17:44","pubTimestamp":1767347081,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，12月30日，新加坡政府投资公司增持复宏汉霖(02696)17.7万股，每股作价56.7593港元，总金额约为1004.64万港元。增持后最新持股数目为991.71万股，最新持股比例为6.07%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1388181.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000165453.HKD","02696","BK1161"],"gpt_icon":0},{"id":"2600094092","title":"每日卖空追踪 | 复宏汉霖 01月02日卖空量成交1.17万股，卖空比例为3.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2600094092","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600094092?lang=zh_cn&edition=full","pubTime":"2026-01-02 16:30","pubTimestamp":1767342634,"startTime":"0","endTime":"0","summary":"复宏汉霖北京时间01月02日，涨2.72%，卖空量成交1.17万股，较上一交易日增加138.78%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260102163408a6eb2aec&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260102163408a6eb2aec&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02696","HK0000165453.HKD","BK1161"],"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":0.0982},{"period":"1month","weight":0.061},{"period":"3month","weight":-0.0207},{"period":"6month","weight":0.0827},{"period":"1year","weight":2.0556},{"period":"ytd","weight":0.2051}],"compareEarnings":[{"period":"1week","weight":0.0052},{"period":"1month","weight":0.0336},{"period":"3month","weight":0.0362},{"period":"6month","weight":0.0959},{"period":"1year","weight":0.4225},{"period":"ytd","weight":0.0475}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"上海复宏汉霖生物技术股份有限公司是一家主要从事生物制药研发、生物制药服务及生物制药生产与销售的中国公司。该公司的主要产品包括汉曲优（注射用曲妥珠单抗）、汉奈佳（马来酸奈拉替尼片）、汉斯状（斯鲁利单抗注射液）、汉利康（利妥昔单抗注射液）、汉达远（阿达木单抗注射液）、汉贝泰（贝伐珠单抗注射液）等。该公司的产品主要应用于乳腺癌辅助治疗、转移性乳腺癌及转移性胃癌治疗、转移性非鳞状非小细胞肺癌、多关节型幼年特发性关节炎治疗等。该公司主要在中国国内和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":-0.015722},{"month":2,"riseRate":0.666667,"avgChangeRate":0.108951},{"month":3,"riseRate":0.5,"avgChangeRate":-0.016995},{"month":4,"riseRate":0.833333,"avgChangeRate":0.128587},{"month":5,"riseRate":0.5,"avgChangeRate":-0.024483},{"month":6,"riseRate":0.666667,"avgChangeRate":0.109389},{"month":7,"riseRate":0.5,"avgChangeRate":0.069459},{"month":8,"riseRate":0.5,"avgChangeRate":-0.024213},{"month":9,"riseRate":0,"avgChangeRate":-0.127435},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.025526},{"month":11,"riseRate":0.571429,"avgChangeRate":0.058675},{"month":12,"riseRate":0.714286,"avgChangeRate":-0.023816}],"exchange":"SEHK","name":"复宏汉霖","nameEN":"HENLIUS"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"复宏汉霖(02696)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供复宏汉霖(02696)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"复宏汉霖,02696,复宏汉霖股票,复宏汉霖股票老虎,复宏汉霖股票老虎国际,复宏汉霖行情,复宏汉霖股票行情,复宏汉霖股价,复宏汉霖股市,复宏汉霖股票价格,复宏汉霖股票交易,复宏汉霖股票购买,复宏汉霖股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"复宏汉霖(02696)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供复宏汉霖(02696)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}